Smart Phone Reader Detects Common Pathogens
|
By LabMedica International staff writers Posted on 10 May 2018 |

Image: The low-cost, portable laboratory on a phone that can interpret results from a microplate assay (Photo courtesy of Washington State University).
In rural or low resource areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.
A low-cost, portable laboratory on a phone has been developed that works nearly as well as clinical laboratories to detect common viral and bacterial infections. The work could lead to faster and lower-cost laboratory results for fast-moving viral and bacterial epidemics.
Bioengineers at Washington State University (Pullman, WA, USA) and their colleagues developed an ultra-low-cost clinically accurate mobile phone microplate reader (mReader), and clinically validated this optical device for 12 infectious disease tests. The mReader optically reads 96 samples on a microplate at one time. The team tested 771 de-identified patient samples for 12 serology assays for bacterial/viral infections. The mReader and the clinical instrument blindly read and analyzed all tests in parallel.
The scientists evaluated the analytical accuracy and the diagnostic performance of the mReader across the clinical reportable categories by comparison with clinical laboratorial testing results. The mReader exhibited 97.6% to 99.9% analytical accuracy and <5% coefficient of variation (CV). The positive percent agreement (PPA) in all 12 tests achieved 100%, negative percent agreement (NPA) was higher than 83% except for one test (42.9%), and overall percent agreement (OPA) ranged 89.3% to100%. The team was able to build the device for about USD 50, but the manufacturing cost would probably be lower than that.
The authors envision the mReader can benefit underserved areas/populations and low-resource settings in rural clinics/hospitals at a low cost with clinical-level analytical quality. It has the potential to improve health access, speed up healthcare delivery, and reduce health disparities and education disparities by providing access to a low-cost spectrophotometer. The study was published on March 23, 2018, in the journal Clinica Chimica Acta.
Related Links:
Washington State University
A low-cost, portable laboratory on a phone has been developed that works nearly as well as clinical laboratories to detect common viral and bacterial infections. The work could lead to faster and lower-cost laboratory results for fast-moving viral and bacterial epidemics.
Bioengineers at Washington State University (Pullman, WA, USA) and their colleagues developed an ultra-low-cost clinically accurate mobile phone microplate reader (mReader), and clinically validated this optical device for 12 infectious disease tests. The mReader optically reads 96 samples on a microplate at one time. The team tested 771 de-identified patient samples for 12 serology assays for bacterial/viral infections. The mReader and the clinical instrument blindly read and analyzed all tests in parallel.
The scientists evaluated the analytical accuracy and the diagnostic performance of the mReader across the clinical reportable categories by comparison with clinical laboratorial testing results. The mReader exhibited 97.6% to 99.9% analytical accuracy and <5% coefficient of variation (CV). The positive percent agreement (PPA) in all 12 tests achieved 100%, negative percent agreement (NPA) was higher than 83% except for one test (42.9%), and overall percent agreement (OPA) ranged 89.3% to100%. The team was able to build the device for about USD 50, but the manufacturing cost would probably be lower than that.
The authors envision the mReader can benefit underserved areas/populations and low-resource settings in rural clinics/hospitals at a low cost with clinical-level analytical quality. It has the potential to improve health access, speed up healthcare delivery, and reduce health disparities and education disparities by providing access to a low-cost spectrophotometer. The study was published on March 23, 2018, in the journal Clinica Chimica Acta.
Related Links:
Washington State University
Latest Microbiology News
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Channels
Clinical Chemistry
view channel
Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read more
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








